Last reviewed · How we verify
JNJ39758979
At a glance
| Generic name | JNJ39758979 |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate (PHASE2)
- A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis (PHASE2)
- A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma (PHASE2)
- Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent (PHASE1)
- A Study To Investigate The Effect of JNJ-39758979 on Histamine Induced Itch in Healthy Male Volunteers (PHASE1)
- A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants (PHASE1)
- Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |